NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

2050.05 15.40 (0.76%)

37.28% Gain from 52W Low

140.3K NSE+BSE Volume

NSE 19 Mar, 2025 12:01 PM (IST)

93,593.2

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

US FDA Approval

Lupin gets US FDA tentative approval for Amifampridine tablets, with a market size of $306 million See details

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

08 May 2024

2050.05

0.76%

Niche product drives earnings growth

Neutral: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) delivered in-line operational performance in 4QFY24. LPC ended
FY24 on a strong note, with INR198b in sales (up 19% YoY), EBITDA margin of
18% (up 750bp YoY) and PAT of INR19b (vs. INR4b YoY). LPC continues to
implement efforts toward building a complex product pipeline in inhalation,
injectables and ophthalmics.

Lupin Ltd.'s price crossed above 30Day SMA today

Lupin Ltd.

07 May 2024

2050.05

0.76%

Mixed Earnings; healthy pipeline of complex products to drive growth

Buy: Lupin Ltd.

Sharekhan

Lupin reported a mix set of earnings where sales were 4% below our estimates at Rs. 4,895 crore. EBITDA was 4% below our estimates at Rs. 997 crore, while adjusted PAT was in-line with our estimate of Rs. 561 crore.

Lupin Ltd.'s price crossed above 200Day SMA today

Lupin Ltd.

24 Apr 2024

2050.05

0.76%

Company Update:Lupin

Buy: Lupin Ltd.

Axis Direct

Niche product approvals and a strong pipeline of new drugs could drive Revenue/PAT CAGR by 10%/19.5% over FY24E-FY26E. We maintain our BUY rating with a Target Price of Rs 1,770/share.

Lupin Ltd.'s price crossed above 200Day SMA today

Lupin Ltd.

15 Apr 2024

2050.05

0.76%

Lupin

Buy: Lupin Ltd.

Recommendation Target

Sharekhan

Lupin Ltd.'s price crossed above 30Day SMA today

Lupin Ltd.

15 Apr 2024

2050.05

0.76%

gSpiriva on a healthy growth track, headwinds receding

Buy: Lupin Ltd.

Recommendation Target

Sharekhan

Lupin has recently received approval for a generic version of Oracea (Doxycycline Capsules) in the US market. The company has received approval for 40MG in the US, which is expected to have sales of $128 million in the US market. Lupin has a healthy pipeline of complex generic products in the US market which would aid the company in achieving quarterly US sales of $200-220 million.

Lupin Ltd. is trading above its 200 day SMA of 2035.1

Lupin Ltd.

13 Feb 2024

2050.05

0.76%

Pick of the Week Lupin Ltd

Buy: Lupin Ltd.

SBI Securities

Lupin Ltd.'s price crossed above 30Day SMA today

Lupin Ltd.

12 Feb 2024

2050.05

0.76%

Double Digit growth in the US in FY25E –FY26E and further margin expansion, key monitorables

Accumulate: Lupin Ltd.

Target

KRChoksey

Lupin reported revenue growth of 20.2% YoY (+ 3.2% QoQ) to INR 51,974 Mn (vs our estimate of Rs. 49,064 Mn) in Q3FY24. It was driven by 21.2% YoY (+2.8% QoQ) increase in Formulations’ revenue (~94.5% of revenue) and a 1.3% YoY (+3.5% QoQ) decline in API revenue (~5.5% of revenue).

Lupin Ltd. has gained 26.99% in the last 1 Year

Lupin Ltd.

09 Feb 2024

2050.05

0.76%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

Double-digit growth in India business as the company has already increased MR numbers to 1,000, 4) An uptick in the API business as the API industry is witnessing demand revival. Recommendation: BUY